How India Exports Paracetamol-caffeine to the World

In the United States, paracetamol (known as acetaminophen) combined with caffeine is commonly used for the treatment of headaches and other pain-related conditions. The FDA's Orange Book lists several approved New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs) for such combinations. For instance, an NDA for a combination of aspirin, butalbital, caffeine, and codeine phosphate capsules was approved on March 5, 1999. However, specific ANDA approvals for paracetamol-caffeine combinations are not prominently listed, indicating that while such combinations are available, they may not be as prevalent in the US market.

The regulatory pathway for these combinations involves demonstrating bioequivalence to a reference listed drug, ensuring compliance with Current Good Manufacturing Practices (cGMP), and adhering to labeling requirements that inform consumers about potential risks, especially concerning liver damage associated with acetaminophen and the stimulant effects of caffeine. Given the presence of 31 active Indian exporters, it is crucial for these entities to stay updated on FDA regulations to maintain market access.

In the European Union and the United Kingdom, paracetamol-caffeine combinations are subject to stringent regulatory oversight. The European Medicines Agency (EMA) conducts periodic safety update report single assessments (PSUSAs) for such combinations. For example, a PSUSA procedure (PSUSA/00002312/202506) was initiated in March 2026, covering combinations like caffeine, codeine, paracetamol, and propyphenazone. (ema.europa.eu) These assessments ensure that the benefit-risk balance of these medicines remains favorable.

The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK also monitors these combinations. In March 2015, the MHRA reviewed the promotion of Syndol Headache Relief Tablets, which contain paracetamol, codeine, and caffeine, to ensure compliance with advertising regulations. (gov.uk) Manufacturers must comply with EU Good Manufacturing Practice (GMP) guidelines, which encompass quality management, personnel, premises, equipment, documentation, production, quality control, and self-inspection.

Paracetamol is listed in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in basic healthcare systems. While caffeine is not listed separately, its combination with paracetamol is recognized for its enhanced analgesic effect. The WHO Prequalification Programme does not specifically list paracetamol-caffeine combinations, but individual components must meet international pharmacopoeia standards. These include the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality, safety, and efficacy.

In India, paracetamol-caffeine combinations are classified under Schedule H of the Drugs and Cosmetics Act, indicating that they are prescription-only medicines. The Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA), regulates the pricing of essential medicines. As of March 2026, paracetamol is under price control, but specific ceiling prices for paracetamol-caffeine combinations are not separately listed. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pharmaceutical products, ensuring compliance with national regulations.

Paracetamol and caffeine are well-established compounds with expired patents, allowing for generic competition. This has led to a competitive market with multiple manufacturers producing paracetamol-caffeine combinations. The absence of active patents facilitates the export of these combinations from India to various international markets without infringement concerns.

In March 2026, the EMA initiated a PSUSA procedure (PSUSA/00002312/202506) for combinations including caffeine, codeine, paracetamol, and propyphenazone, reflecting ongoing pharmacovigilance efforts. (ema.europa.eu) In July 2025, the EMA published a list of nationally authorized medicinal products containing acetylsalicylic acid, caffeine, and paracetamol, indicating continued regulatory oversight. (ema.europa.eu) In June 2025, the UK's Food Standards Agency updated guidance for food business operators on food supplements containing caffeine, emphasizing the importance of accurate labeling and consumer safety. (food.gov.uk) In April 2025, the UK's Food Standards Agency provided guidance on the authorization requirements for extraction solvents, including those used in caffeine extraction, highlighting the need for compliance with safety standards. (food.gov.uk) In September 2024, the UK's Food Standards Agency issued advice on food supplements containing caffeine, focusing on consumer awareness and safe consumption practices. (food.gov.uk)

These developments underscore the dynamic regulatory environment surrounding paracetamol-caffeine combinations, necessitating continuous monitoring and compliance by exporters to ensure market access and consumer safety.

India's pharmaceutical industry, renowned for its generic drug production, heavily relies on China for key starting materials (KSMs) essential in manufacturing active pharmaceutical ingredients (APIs). This dependency is particularly pronounced in the production of paracetamol and caffeine, the primary components of paracetamol-caffeine formulations. For instance, Farmson Pharmaceutical Guj Pvt Ltd, a leading Indian manufacturer, produces approximately 96.1 billion paracetamol tablets annually, underscoring the scale of production reliant on these raw materials. (ensun.io)

The COVID-19 pandemic in early 2020 exposed the vulnerabilities of this supply chain. Disruptions in Chinese manufacturing led to immediate shortages and price surges for essential drugs like paracetamol. This event highlighted the critical need for India to develop domestic capabilities in producing KSMs to mitigate future risks associated with external dependencies.

Analysis of TransData Nexus's proprietary trade data from 2022 to 2026 reveals a significant concentration among Indian exporters of paracetamol-caffeine. The top five exporters account for 72.2% of total exports, with BASE PHARMACY INDIA alone contributing 48.2%. Such concentration poses a single-source risk, where disruptions affecting these key suppliers could severely impact the global supply chain.

To address these concerns, the Indian government introduced the Production Linked Incentive (PLI) scheme in 2020, aiming to boost domestic manufacturing of critical APIs and KSMs. By November 2024, two greenfield plants were inaugurated under this scheme to produce essential molecules like Penicillin G and 6-APA, marking a significant step towards reducing import dependence.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are susceptible to geopolitical tensions that can disrupt the transportation of pharmaceutical ingredients. Additionally, ongoing U.S.-China trade tensions have the potential to affect the availability and pricing of Chinese-sourced KSMs. Such disruptions can lead to shortages and increased costs in the pharmaceutical supply chain.

Regulatory bodies like the U.S. Food and Drug Administration (FDA) have issued alerts regarding drug shortages resulting from these supply chain vulnerabilities. For example, in March 2024, the FDA highlighted shortages of certain medications due to supply chain disruptions, emphasizing the need for diversified sourcing strategies.

• Diversify Supplier Base: Encourage the development of alternative suppliers within India and other countries to reduce reliance on a limited number of exporters.

• Enhance Domestic Production: Support initiatives like the PLI scheme to bolster domestic manufacturing of APIs and KSMs, thereby decreasing dependence on imports.

• Strengthen Supply Chain Resilience: Implement robust risk assessment and management strategies to anticipate and mitigate potential disruptions in the supply chain.

• Monitor Geopolitical Developments: Stay informed about international relations and trade policies that could impact the availability of pharmaceutical ingredients.

• Engage with Regulatory Bodies: Collaborate with organizations like the FDA and WHO to stay updated on potential shortages and compliance requirements.

RISK_LEVEL: MEDIUM